Oxaliplatin pharmacokinetics during a four-hour infusion

Clinical Cancer Research

Volumn 5, Issue 4, 1999, Pages 761-765

  Kern, Wolfgang ^a   Braess, Jan ^a   Böttger, Bettina ^b   Kaufmann, Cornelia Christine ^b   Hiddemann, Wolfgang ^a   Schleyer, Eberhard ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

OXALIPLATIN;

ADULT; ARTICLE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EXCRETION; DRUG HALF LIFE; DRUG PROTEIN BINDING; HUMAN; KIDNEY CLEARANCE; PRIORITY JOURNAL;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARCINOMA; COLORECTAL NEOPLASMS; COMPUTER SIMULATION; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; MODELS, BIOLOGICAL; ORGANOPLATINUM COMPOUNDS;

EID: 0032930471     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Wingo, P. A., Ries, L. A., Rosenberg, H. M., Miller, D. S., and Edwards, B. K. Cancer incidence and mortality, 1973-1995: a report card for the U. S. Cancer (Phila.), 82: 1197-1207, 1998.
2. Misset, J. L. Oxaliplatin in practice. Br. J. Cancer, 77: 4-7, 1998.
3. Bleiberg, H., and de Gramont, A. Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer. Semin. Oncol., 25: 32-39, 1998.
4. Punt, C. J. New drugs in the treatment of colorectal carcinoma. Cancer (Phila.), 83: 679-689, 1998.
5. Blackledge, G. New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex'). Br. J. Cancer, 77 (Suppl. 2): 29-37, 1998.
6. Bleiberg, H. Continuing the fight against advanced colorectal cancer: new and future treatment options. Anticancer Drugs, 9: 18-28, 1998.
7. Weiss, R. B., and Christian, M. C. New cisplatin analogues in development. A review. Drags, 46: 360-377, 1993.
8. Cvitkovic, E. Ongoing and unsaid on oxaliplatin: the hope. Br. J. Cancer. 77: 8-11, 1998.
9. Fink, D., Zheng, H., Nebel, S., Norris, P. S., Aebi, S., Lin, T. P., Nehme, A., Christen, R. D., Haas, M., MacLeod, C. L., and Howell, S. B. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res., 57: 1841-1845, 1997.
10. Fink, D., Nebel, S., Aebi, S., Zheng, H., Cenni, B., Nehme, A., Christen, R. D., and Howell, S. B. The role of DNA mismatch repair in platinum drug resistance. Cancer Res., 56: 4881-4886, 1996.
11. Vaisman, A., Varchenko, M., Umar, A., Kunkel, T. A., Risinger, J. I., Barrett, J. C., Hamilton, T. C., and Chaney, S. G. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res., 58: 3579-3585, 1998.
12. Raymond, E., Lawrence, R., Izbicka, E., Faivre, S., and Von Hoff, D. D. Activity of oxaliplatin against human tumor colony-forming units. Clin. Cancer Res., 4: 1021-1029, 1998.
13. Rixe, O., Ortuzar, W., Alvarez, M., Parker, R., Reed, E., Paull, K., and Fojo, T. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem. Pharmacol., 52: 1855-1865, 1996.
14. Pendyala, L., Kidani, Y., Perez, R., Wilkes, J., Bernacki, R. J., and Creaven, P. J. Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. Cancer Lett., 97: 177-184, 1995.
15. Becouarn, Y., Ychou, M., Ducreux, M., Borel, C., Bertheault-Cvitkovic, F., Seitz, J. F., Nasca, S., Nguyen, T. D., Paillot, B., Raoul, J. L., Duffour, J., Fandi, A., Dupont-Andre, G., and Rougier, P. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J. Clin. Oncol., 16: 2739-2744, 1998.
16. Diaz Rubio, E., Sastre, J., Zaniboni, A., Labianca, R., Cortes Funes, H., de Braud, F., Boni, C., Benavides, M., Dallavalle, G., and Homerin, M. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a Phase II multicentric study. Ann. Oncol., 9: 105-108, 1998.
17. Extra, J. M., Espie, M., Calvo, F., Ferme, C., Mignot, L., and Marty, M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother. Pharmacol., 25: 299-303, 1990.
18. Mathe, G., Kidani, Y., Triana, K., Brienza, S., Ribaud, P., Goldschmidt, E., Ecstein, E., Despax, R., Musset, M., and Misset, J. L. A Phase I trial of trans-1-diaminocyclohexane oxalato-platinum (1-OHP). Biomed. Pharmacother., 40: 372-376, 1986.
19. Bleiberg, H. Oxaliplatin (L-OHP). a new reality in colorectal cancer. Br. J. Cancer, 77: 1-3, 1998.
20. deBraud, F., Munzone, E., Nole, F., De Pas, T., Biffi, R., Brienza, S., and Aapro, M. S. Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil. Am. J. Clin. Oncol., 21: 279-283, 1998.
21. Becouarn, Y., and Rougier, P. Clinical efficacy of oxaliplatin monotherapy: Phase II trials in advanced colorectal cancer. Semin. Oncol., 25: 23-31, 1998.
22. Gerard, B., Bleiberg, H., Van Daele, D., Gil, T., Hendlisz, A., Di Leo, A., Fernez, B., and Brienza, S. Oxaliplatin combined to 5-fluorouracil and folinic acid: an effective therapy in patients with advanced colorectal cancer. Anticancer Drugs, 9: 301-305, 1998.
23. de Gramont, A., Tournigand, C., Louvet, C., Andre, T., Molitor, J. L., Raymond, E., Moreau, S., Vignoud, J., Le Bail, N., and Krulik, M. Oxaliplatin, folinic acid and 5-fluorouracil (folfox) in pretreated patients with metastatic advanced cancer. The GERCOD. Rev. Med. Intern., 18: 769-775, 1997.
24. de Gramont, A., Vignoud, J., Tournigand, C., Louvet, C., Andre, T., Varette, C., Raymond, E., Moreau, S., Le Bail, N., and Krulik, M. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur. J. Cancer, 33: 214-219, 1997.
25. Machover, D., Diaz Rubio, E., de Gramont, A., Schilf, A., Gastiaburu, J. J., Brienza, S., Itzhaki, M., Metzger, G., N'Daw, D., Vignoud, J., Abad, A., Francois, E., Gamelin, E., Marty, M., Sastre, J., Seitz, J. F., and Ychou, M. Two consecutive Phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann. Oncol., 7: 95-98, 1996.
26. Levi, F., Zidani, R., and Misset, J. L. Randomised multicentrc trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet, 350: 681-686, 1997.
27. Bertheault Cvitkovic, F., Jami, A., Ithzaki, M., Brummer, P. D., Brienza, S., Adam, R., Kunstlinger, F., Bismuth, H., Misset, J. L., and Levi, F. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J. Clin. Oncol., 14: 2950-2958, 1996.
28. Levi, F. A., Zidani, R., Vannetzel, J. M., Perpoint, B., Focan, C., Faggiuolo, R., Chollet, P., Garufi, C., Itzhaki, M., Dogliotti, L., et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multiinstitutional trial. J. Natl. Cancer Inst. (Bethesda), 86: 1608-1617, 1994.
29. Caussanel, J. P., Levi, F., Brienza, S., Misset, J. L., Itzhaki, M., Adam, R., Milano, G., Hecquel, B., and Mathe, G. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J. Natl. Cancer Inst. (Bethesda), 82: 1046-1050, 1990.
30. Levi, F. Chronotherapy for gastrointestinal cancers. Curr. Opin. Oncol., 8: 334-341, 1996.
31. Sandor, V. Chronotherapy with 5-fluorouracil, oxaliplatin, and folinic acid in colorectal cancer. Lancet, 350: 1325-1326, 1997.
32. Extra, J. M., Marty, M., Brienza, S., and Misset, J. L. Pharmacokinetics and safety profile of oxaliplatin. Semin. Oncol., 25: 13-22, 1998.
33. Metzger, G., Massari, C., Renée, N., Mormont, M. C., Milano, G., and Levi, F. Variations in platinum (Pt) plasma levels depending on chronomodulated oxaliplatin (1-OHP) peak lime. Proc. Am. Soc. Clin. Oncol., 16: 244a, 1997.
34. Machover, D., Goldschmidt, E., Chollet, P., Metzger, G., Zittoun, J., Marquel, J., Vandenbulcke, J. M., Misset, J. L., Schwarzenberg, L., Fourtillan, J. B., et al. Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J. Clin. Oncol., 4: 685-696, 1986.
35. Ardalan, B., Chua, L., Tian, E. M., Reddy, R., Sridhar, K., Benedetto, P., Richman, S., Legaspi, A., Waldman, S., Morrell, L., et al. A Phase II sludy of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J. Clin Oncol., 9: 625-630, 1991.
36. Kern, W., Braess, J., Samel, S., Post, S., Becker, H., Hiddemann, W., and Schleyer, E. Pharmacokinetics of cisplatin and its impact on nephrotoxicity during intraoperalive hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer. In: J. Siewert and J. Roder (eds.), Progress in Gastric Cancer Research 1997, Vol. 2, pp. 1387-1391. Italy: Monduzzi Editore, International Proceedings Division, 1997.
37. Heinzel, G., Hammer, R., Wolf, M., Koss, F. W., and Bozler, G. Model building in pharmacokinetics. Part III: Simplified rules for the deduction of analytical solutions for linear compartment models. Arzneimittelforschung, 27: 904-911, 1977.
38. Hiddemann, W., Schleyer, E., Unterhalt, M., Kern, W., and Buchner, T. Optimizing therapy for acute myeloid leukemia based on differences in intracellular metabolism of 1-β-D-arabinofuranosylcytosine between leukemic blasts and normal mononuclear blood cells. Ther. Drug Monit., 18: 341-349, 1996.
39. Pinedo, H. M., and Peters, G. F. Fluorouracil: biochemistry and pharmacology. J. Clin. Oncol., 6: 1653-1664, 1988.
40. Lokiec, F., Wasserman, E., Cvitkovic, E., Santoni, J., Weill, S., Gauzan, M. F., and Misset, J. L. Final results of the pharmacokinetic study of both CPT-11 (C) and LOHP (L) in combination during a Phase I trial in gastrointestinal cancer patients. Proc. Am. Soc. Clin. Oncol., 17: 202a, 1998.
41. Lokiec, F., Wasserman, E., Santoni, J., Mahjoubi, M., Misset, J. L., and Cvitkovic, E. Pharmacokinetics (PK) of the irinotecan/oxaliplatin (LOHP) combinalion: preliminary data of an ongoing Phase I trial. Proc. Am. Soc. Clin. Oncol., 16: 203a, 1997.
42. Gamelin, E., Le Bouil, A., Boisdron-Celle, M., Turcant, A., Delva, R., Cailleux, A., Krikorian, A., Brienza, S., Cvitkovic, E., Robert, J., Larra, F., and Allain, P. Cumulative pharmacokinetic study of oxaliplatin, adminislered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. Clin. Cancer Res., 3: 891-899, 1997.
43. Grumblat, A., Peylavin, G., Vayre, P., Chapuis, P., Fredj, G., and Mathe, G. Comparative pharmacokinetics of oxaliplatin after intraperitoneal and intravenous administration. Bull. Cancer, 76: 887-888, 1989.
44. Allen, J., Graham, M. A., Firth, J., Woolfrey, S., Greenslade, D., Morrison, J. G., McDougall, S., Ross, P., and Cunningham, D. Biotransformation and pharmacokinetic analysis of oxaliplatin in patients with advanced gastrointestinal cancer. Proc. Am. Assoc. Cancer. Res., 39: 159, 1998.
45. Graham, M. A., Gamelin, E., Misset, J. L., Brienza, S., Allain, P., Boisdron-Celle, M., Krikorian, A., Greenslade, D., and Bayssas, M. Clinical pharmacokinetics of oxaliplatin. Proc. Am. Assoc. Cancer. Res., 39: 159, 1998.
46. Gamelin, E., Boisdron-Celle, M., Lebouil, A., Turcant, A., Cailleux, A., Krikorian, A., Brienza, S., Cvitkovic, E., Larra, F., Robert, J., and Allain, P. Determination of unbound platinum after oxaliplatin administration: comparison of currently available methods and influence of various parameters. Anticancer Drugs, 9: 223-228, 1998.
47. Pendyala, L., and Creaven, P. J. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res., 55: 5970-5976, 1993.
48. Pendyala, L., Seng, J., Creaven, P. J., and Grandjean, E. M. Studies on the plasma protein binding and red blood cell (RBC) partitioning of oxaliplatin in vitro. Anticancer Drug Des., 6: 281-282, 1991.
49. Kizu, R., Higashi, S., Kidani, Y., and Miyazaki, M. Pharmacokinetics of (1 R,2S-diaminocyclohexane)oxalatoplatinum(II) in comparison with cisplatin following a single intravenous injection in rabbits. Cancer Chemother. Pharmacol., 31: 475-480, 1993.
50. Calvert, H., Judson, I., and van der Vijgh, W. J. Platinum complexes in cancer medicine: pharmacokinetics and pharmacodynamics in relation to toxicity and therapeutic activity. Cancer Surv., 17: 189-217, 1993.
51. Levi, F., Giacchetti, S., Adam, R., Zidani, R., Metzger, G., and Misset, J. L. Chronomodulation of chemotherapy against metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Eur. J. Cancer, 31 A: 1264-1270, 1995.
52. Levi, F. Chronotherapy of cancer: biological basis and clinical application. Pathol. Biol. Paris, 42: 338-341, 1994.